Adolescence is a period of profound developmental changes, which run the gamut from behavioral and neural to physiological and hormonal. It is also a time at which there is an increased propensity to engage in risk-taking and impulsive behaviors like drug use. This review examines the human and preclinical literature on adolescent drug use and its consequences, with a focus on dissociatives...
The Problem of Pain Sophie Pinkham (bio) White Market Drugs: Big Pharma and the Hidden History of Addiction in America by David Herzberg University of Chicago Press, 2020, 400 pp. Click for larger view View full resolution A worker removes the Sackler name from a building at Tufts University in 2019. (David L. Ryan/The Boston Globe via Getty Images) [End Page 130] Reams have been written about...
In this article, we present an evaluation of online psychoactive substance trade via Telegram, a free encrypted social media messenger service. The evaluation took place during the COVID-19 pandemic, which allowed us to monitor the effects of the spring 2020 lockdown in the Netherlands on substance trade via Telegram. The objective of this study was to evaluate whether changes in psychoactive...
N-methyl-D-aspartate receptor (NMDAR) antagonists administered to healthy humans results in schizophrenia-like symptoms, which are thought in part to be related to glutamatergically altered electrophysiological connectivity in large-scale intrinsic functional brain networks. Here, we examine resting-state source electroencephalographic (EEG) connectivity within and between the default mode...
The cognitive functions of human and non-human primates rely on the dynamic interplay of distributed neural assemblies. As such, it seems unlikely that cognition can be supported by macroscopic brain dynamics at the proximity of thermodynamic equilibrium. We confirmed this hypothesis by investigating electrocorticography data from non human primates undergoing different states of...
By systematically tweaking the structure of the psychedelic compound ibogaine, chemists have created a molecule that may someday find use as a treatment for neuropsychiatric disorders, including depression and addiction. The compound, which the researchers call tabernanthalog, has a simpler structure than ibogaine, making it easier to synthesize. Researchers in David E. Olson’s lab at the...
Mounting evidence suggests safety and efficacy of psychedelic compounds as potential novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug Administration in a new class of antidepressants, and 3,4-methylenedioxymethamphetamine (MDMA) is undergoing phase III clinical trials for post-traumatic stress disorder. Psilocybin and lysergic acid diethylamide (LSD) are being...
December 1, 2020Caroline Mathon, Christèle Widmer, R. Mégevand et al.
Objectif Depuis de nombreuses annees, la politique en matiere de drogues est basee en Suisse sur quatre piliers, a savoir la prevention, la therapie, la repression et la reduction des risques. Parmi les actions mises en œuvre concernant la reduction des risques lies aux consommations recreatives de substances psychoactives, une nouvelle offre a ete proposee depuis 2019 a Geneve, consistant en...
The hypothesis of monoaminergic deficiency has long dominated the conceptual framework for the development of new antidepressant strategies, but the limits of conventional antidepressant treatments targeting monoaminergic signaling have motivated the search for new antidepressant pathways. The success of ketamine in the management of depressive disorders has provoked a renewed interest in...
Abstract As these words are written, the chemical we will call MDMA is a Schedule I drug. This means that MDMA (a) has no currently accepted medical use, (b) no currently accepted safety even under medical supervision, and (c) has a high potential for abuse. On the other hand, there are those who see great therapeutic potential in MDMA, and the Food and Drug Administration (FDA) has designated...